Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 ROE % is 13.82% as of Mar. 2026, which is 733% above its 10-year median of 1.66. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 935 Drug Manufacturers companies, Vilin Bio Med ranks better than 53.48% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vilin Bio Med's annualized net income for the quarter that ended in Mar. 2026 was ₹35.5 Mil. Vilin Bio Med's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹257.2 Mil. Therefore, Vilin Bio Med's annualized ROE % for the quarter that ended in Mar. 2026 was 13.82%.
The historical rank and industry rank for Vilin Bio Med's ROE % or its related term are showing as below:
NSE:VILINBIO'
s ROE % Range Over the Past 10 Years
Min: 0.45 Med: 1.66 Max: 13.78
Current: 6.91
During the past 7 years, Vilin Bio Med's highest ROE % was 13.78%. The lowest was 0.45%. And the median was 1.66%.
NSE:VILINBIO's ROE % is ranked better than 53.48% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6.18
vs NSE:VILINBIO: 6.91
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Vilin Bio Med ROE % Related Terms
Vilin Bio Med ROE % Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's ROE % distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Vilin Bio Med (NSE:VILINBIO) has a ROE % of 13.82% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vilin Bio Med and its competitors. This is 733% above median its historical median of 1.66. Over the past decade, Vilin Bio Med's ROE % has ranged from 0.45 to 13.78. According to the industry distribution chart, Vilin Bio Med ranks #435 out of 935 companies in the Drug Manufacturers industry, placing it in the top 46.5%.
Is Vilin Bio Med's ROE % too high?
Vilin Bio Med's current ROE % of 13.82% is 733% above median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 13.78. The Drug Manufacturers industry median ROE % is 6.18. Vilin Bio Med's value of 13.82% is 123.6% above this industry median. Based on the distribution chart, Vilin Bio Med ranks #435 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #435 out of 935 companies for ROE %. This puts Vilin Bio Med in the upper half of its industry. The industry median ROE % is 6.18. Vilin Bio Med's value of 13.82% is 123.6% above this benchmark. Historically, Vilin Bio Med's own ROE % has ranged from 0.45 to 13.78 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 6.18, Vilin Bio Med has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.18, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current ROE % of 13.82% is 123.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current ROE % is 13.82%, which is 733% above median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current ROE % is 13.82%, which is 733% above median its 10-year median of 1.66 and 123.6% above the Drug Manufacturers industry median of 6.18. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current ROE % is 13.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
ROE %: 13.82% (733% above median its 10-year median of 1.66)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 123.6% above the Drug Manufacturers median (#435 of 935)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
